"Is Clinical Supply the Weakest Link in Your Chain?" by Benedict Hirth, MYONEX
In his presentation at the recent COG New England meeting, Benedict Hirth, Global Lead Manager Supply Chain Optimization at MYONEX, illuminated the critical importance of a robust supply chain in the success of clinical trials. Benedict emphasised that in the complex and evolving landscape of clinical trials, a well-managed supply chain can make the difference between a successful trial and one that falls short of its objectives.
Benedict began by highlighting the current trends in clinical trial supply, including the growing complexity of trial designs, the increasing focus on sustainability, and the evolution of regulatory landscapes. He also discussed the emergence of alternative supply strategies and the adoption of new technologies in the field.
The presentation then delved into the potential risks facing clinical supply chains, such as delayed drug availability and drug shortages. Benedict explained how these issues can lead to increased enrolment targets, additional costs, and challenges in patient retention and recruitment. He also touched upon the data integrity risks and financial implications that can arise from supply chain disruptions.
A key takeaway from Benedict's presentation was the importance of proactive supply management as a priority. He stressed the need for organisations to stay ahead of the game by recognising risks and trends in the industry. He also highlighted the value of outsourcing service models and integrated technology solutions, such as advanced IRT systems and supply chain simulation, in ensuring a robust and resilient supply chain.
Throughout his presentation, Benedict emphasised the critical role of the supply chain in the success of clinical trials, stating, "If there is no drug, there is no clinical trial." His message was clear: organisations must prioritize supply chain excellence to mitigate risks, ensure data integrity, and ultimately, deliver successful clinical trials.
コメント